Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.

Saved in:
Bibliographic Details
Title: Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.
Authors: Klingler J; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; James J. Peters VA Medical Center, Bronx, NY, United States., Kowdle S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Bandres JC; James J. Peters VA Medical Center, Bronx, NY, United States., Emami-Gorizi R; James J. Peters VA Medical Center, Bronx, NY, United States., Alvarez RA; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Rao PG; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Amanat F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Gleason C; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Kleiner G; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Simon V; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Edelstein A; Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina., Perandones C; Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina., Upadhyay C; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Lee B; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Hioe CE; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; James J. Peters VA Medical Center, Bronx, NY, United States.
Source: Frontiers in immunology [Front Immunol] 2024 May 08; Vol. 15, pp. 1382619. Date of Electronic Publication: 2024 May 08 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1382619